文献速递间质性肺疾病

特发性肺纤维化抗纤维化治疗的种族与民族差异

Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis.
PubMed 文献 · Respirology · 2023-08-03

该研究利用TriNetX数据库纳入47184例成人特发性肺纤维化患者,按种族配对比较抗纤维化治疗使用情况。结果显示黑人患者抗纤维化使用率显著低于白人、西班牙裔和亚裔患者,且仅在白人患者中抗纤维化治疗与死亡率降低相关。

要点

  • 黑人IPF患者抗纤维化治疗使用率显著低于白人、西班牙裔和亚裔患者。
  • 在白人患者中,抗纤维化治疗与死亡率降低相关,其他种族未见此关联。
  • >65岁及肺功能较低的黑人亚组中同样存在治疗差异。

核心结论

  • 黑人IPF患者抗纤维化治疗使用率低于白人、西班牙裔和亚裔患者。
  • 仅在白人患者中观察到抗纤维化治疗与死亡率降低相关。
  • 研究提示需紧急行动探究IPF治疗中种族差异的原因。

研究设计与样本

  • 基于TriNetX数据库的回顾性队列研究,纳入年龄>18岁的成人特发性肺纤维化患者。
  • 共识别47184例IPF患者,其中白人35082例、西班牙裔6079例、黑人5245例、亚裔1221例。
  • 采用配对比较分析抗纤维化治疗使用情况,并对年龄、性别、尼古丁依赖、氧依赖和预测FVC进行倾向评分匹配后比较治疗与未治疗患者的死亡率。
  • 额外在>65岁和肺功能较低的IPF患者亚组中进行比较。

主要发现

  • 匹配队列配对比较显示,黑人患者抗纤维化使用率低于白人(6.2% vs. 11.4%,p<0.0001)。
  • 黑人患者抗纤维化使用率低于西班牙裔(10.8% vs. 20.2%,p<0.0001)。
  • 黑人患者抗纤维化使用率低于亚裔(9.6% vs. 14.7%,p=0.0006)。
  • 在>65岁和肺功能较低的黑人亚组中同样观察到类似的治疗差异。
  • 白人患者中接受抗纤维化治疗者死亡率低于未治疗者,而西班牙裔、黑人和亚裔患者中未见此差异。

临床怎么用

  • 临床应关注IPF抗纤维化治疗中可能存在的种族差异,尤其对黑人患者。
  • 对黑人IPF患者应评估抗纤维化治疗的适用性,避免因非医学因素导致治疗不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Racial disparities have been documented in care of many respiratory diseases but little is known about the impact of race on the treatment of interstitial lung diseases. The purpose of this study was to determine how race and ethnicity influence treatment of idiopathic pulmonary fibrosis. METHODS: Adults with idiopathic pulmonary fibrosis (>18 years) were identified using TriNetX database and paired-wised comparisons were performed for antifibrotic treatment among White, Black, Hispanic and Asian patients. Mortality of treated and untreated IPF patients was compared after propensity score matching for age, sex, nicotine dependence, oxygen dependence and predicted FVC. Additional comparisons were performed in subgroups of IPF patients older than 65 years of age and with lower lung function. RESULTS: Of 47,184 IPF patients identified, the majority were White (35,082), followed by Hispanic (6079), Black (5245) and Asian (1221). When subgroups were submitted to matched cohort pair-wise comparisons, anti-fibrotic usage was lower among Black patients compared to White (6.2% vs. 11.4%, p-value <0.0001), Hispanic (10.8% vs. 20.2%, p-value <0.0001) and Asian patients (9.6% vs. 14.7%, p-value = 0.0006). Similar treatment differences were noted in Black individuals older than 65 years and those with lower lung function. Mortality among White patients, but not Hispanic, Black, or Asian patients, was lower in patients on antifibrotic therapy versus not on therapy. CONCLUSION: This study demonstrated that Black IPF patients had lower antifibrotic use compared to White, Hispanic and Asian patients. Our findings suggest that urgent action is needed to understand the reason why racial disparities exist in the treatment of IPF.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Zhao J, Fares J, George G, et al. Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis. Respirology. 2023. PMID: 37534632. doi:10.1111/resp.14563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。